Phase II trial of thalidomide for patients with advanced renal cell carcinoma

Robert J. Motzer, William Berg, Michelle Ginsberg, Paul Russo, Jacqueline Vuky, R. Richard Yu, Jennifer Bacik, Madhu Mazumdar

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Purpose: To assess efficacy and toxicity of thalidomide in patients with advanced renal cell carcinoma (RCC). Patients and Methods: Twenty-six patients with RCC were treated with thalidomide at a starting dose of 200 mg daily. Thalidomide was increased by 200 mg every 2 weeks until a maximum dose of 800 mg or prohibitive toxicity was reached. Fifteen patients had prior nephrectomy, 11 patients had no prior systemic therapy, and 15 had received one prior systemic regimen. Results: A maximum dose of 800 mg, 600 mg, 400 mg, and 200 mg was reached in five, 10, eight, and three patients, respectively. Grade 2 and 3 dyspnea occurred in four and three patients, respectively. Grade 2 and 3 neurologic toxicity was observed in five and two patients, respectively. Of the 25 assessable patients, the best response was stable disease in 16 (95% confidence interval [Cl], 43% to 82%) patients. The 6-month progression-free survival rate was 32% (95% Cl, 14% to 50%). Three patients achieved prolonged stable disease of 16, 16+, and 18+ months, including two patients who were refractory to previous cytokine therapy. Fifty-seven percent were alive at 1 year (95% Cl, 37%, to 76%). Conclusion: This trial does not support the routine use of thalidomide to induce partial response for metastatic RCC. Because disease stabilization occurs as a part of the natural history of metastatic RCC, the potential effect of thalidomide on progression-free and overall survival for patients with advanced RCC is being addressed in a randomized phase III trial. New immunomodulatory analogs of thalidomide that have shown potentially greater antitumor effects in preclinical models warrant study in metastatic RCC.

Original languageEnglish (US)
Pages (from-to)302-306
Number of pages5
JournalJournal of Clinical Oncology
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Thalidomide
Renal Cell Carcinoma
Disease-Free Survival
Nephrectomy
Dyspnea
Nervous System
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Motzer, R. J., Berg, W., Ginsberg, M., Russo, P., Vuky, J., Yu, R. R., ... Mazumdar, M. (2002). Phase II trial of thalidomide for patients with advanced renal cell carcinoma. Journal of Clinical Oncology, 20(1), 302-306. https://doi.org/10.1200/JCO.20.1.302

Phase II trial of thalidomide for patients with advanced renal cell carcinoma. / Motzer, Robert J.; Berg, William; Ginsberg, Michelle; Russo, Paul; Vuky, Jacqueline; Yu, R. Richard; Bacik, Jennifer; Mazumdar, Madhu.

In: Journal of Clinical Oncology, Vol. 20, No. 1, 01.01.2002, p. 302-306.

Research output: Contribution to journalArticle

Motzer, RJ, Berg, W, Ginsberg, M, Russo, P, Vuky, J, Yu, RR, Bacik, J & Mazumdar, M 2002, 'Phase II trial of thalidomide for patients with advanced renal cell carcinoma', Journal of Clinical Oncology, vol. 20, no. 1, pp. 302-306. https://doi.org/10.1200/JCO.20.1.302
Motzer, Robert J. ; Berg, William ; Ginsberg, Michelle ; Russo, Paul ; Vuky, Jacqueline ; Yu, R. Richard ; Bacik, Jennifer ; Mazumdar, Madhu. / Phase II trial of thalidomide for patients with advanced renal cell carcinoma. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 1. pp. 302-306.
@article{8b3b6d889f6547c0b778235ca4c92d9c,
title = "Phase II trial of thalidomide for patients with advanced renal cell carcinoma",
abstract = "Purpose: To assess efficacy and toxicity of thalidomide in patients with advanced renal cell carcinoma (RCC). Patients and Methods: Twenty-six patients with RCC were treated with thalidomide at a starting dose of 200 mg daily. Thalidomide was increased by 200 mg every 2 weeks until a maximum dose of 800 mg or prohibitive toxicity was reached. Fifteen patients had prior nephrectomy, 11 patients had no prior systemic therapy, and 15 had received one prior systemic regimen. Results: A maximum dose of 800 mg, 600 mg, 400 mg, and 200 mg was reached in five, 10, eight, and three patients, respectively. Grade 2 and 3 dyspnea occurred in four and three patients, respectively. Grade 2 and 3 neurologic toxicity was observed in five and two patients, respectively. Of the 25 assessable patients, the best response was stable disease in 16 (95{\%} confidence interval [Cl], 43{\%} to 82{\%}) patients. The 6-month progression-free survival rate was 32{\%} (95{\%} Cl, 14{\%} to 50{\%}). Three patients achieved prolonged stable disease of 16, 16+, and 18+ months, including two patients who were refractory to previous cytokine therapy. Fifty-seven percent were alive at 1 year (95{\%} Cl, 37{\%}, to 76{\%}). Conclusion: This trial does not support the routine use of thalidomide to induce partial response for metastatic RCC. Because disease stabilization occurs as a part of the natural history of metastatic RCC, the potential effect of thalidomide on progression-free and overall survival for patients with advanced RCC is being addressed in a randomized phase III trial. New immunomodulatory analogs of thalidomide that have shown potentially greater antitumor effects in preclinical models warrant study in metastatic RCC.",
author = "Motzer, {Robert J.} and William Berg and Michelle Ginsberg and Paul Russo and Jacqueline Vuky and Yu, {R. Richard} and Jennifer Bacik and Madhu Mazumdar",
year = "2002",
month = "1",
day = "1",
doi = "10.1200/JCO.20.1.302",
language = "English (US)",
volume = "20",
pages = "302--306",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Phase II trial of thalidomide for patients with advanced renal cell carcinoma

AU - Motzer, Robert J.

AU - Berg, William

AU - Ginsberg, Michelle

AU - Russo, Paul

AU - Vuky, Jacqueline

AU - Yu, R. Richard

AU - Bacik, Jennifer

AU - Mazumdar, Madhu

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Purpose: To assess efficacy and toxicity of thalidomide in patients with advanced renal cell carcinoma (RCC). Patients and Methods: Twenty-six patients with RCC were treated with thalidomide at a starting dose of 200 mg daily. Thalidomide was increased by 200 mg every 2 weeks until a maximum dose of 800 mg or prohibitive toxicity was reached. Fifteen patients had prior nephrectomy, 11 patients had no prior systemic therapy, and 15 had received one prior systemic regimen. Results: A maximum dose of 800 mg, 600 mg, 400 mg, and 200 mg was reached in five, 10, eight, and three patients, respectively. Grade 2 and 3 dyspnea occurred in four and three patients, respectively. Grade 2 and 3 neurologic toxicity was observed in five and two patients, respectively. Of the 25 assessable patients, the best response was stable disease in 16 (95% confidence interval [Cl], 43% to 82%) patients. The 6-month progression-free survival rate was 32% (95% Cl, 14% to 50%). Three patients achieved prolonged stable disease of 16, 16+, and 18+ months, including two patients who were refractory to previous cytokine therapy. Fifty-seven percent were alive at 1 year (95% Cl, 37%, to 76%). Conclusion: This trial does not support the routine use of thalidomide to induce partial response for metastatic RCC. Because disease stabilization occurs as a part of the natural history of metastatic RCC, the potential effect of thalidomide on progression-free and overall survival for patients with advanced RCC is being addressed in a randomized phase III trial. New immunomodulatory analogs of thalidomide that have shown potentially greater antitumor effects in preclinical models warrant study in metastatic RCC.

AB - Purpose: To assess efficacy and toxicity of thalidomide in patients with advanced renal cell carcinoma (RCC). Patients and Methods: Twenty-six patients with RCC were treated with thalidomide at a starting dose of 200 mg daily. Thalidomide was increased by 200 mg every 2 weeks until a maximum dose of 800 mg or prohibitive toxicity was reached. Fifteen patients had prior nephrectomy, 11 patients had no prior systemic therapy, and 15 had received one prior systemic regimen. Results: A maximum dose of 800 mg, 600 mg, 400 mg, and 200 mg was reached in five, 10, eight, and three patients, respectively. Grade 2 and 3 dyspnea occurred in four and three patients, respectively. Grade 2 and 3 neurologic toxicity was observed in five and two patients, respectively. Of the 25 assessable patients, the best response was stable disease in 16 (95% confidence interval [Cl], 43% to 82%) patients. The 6-month progression-free survival rate was 32% (95% Cl, 14% to 50%). Three patients achieved prolonged stable disease of 16, 16+, and 18+ months, including two patients who were refractory to previous cytokine therapy. Fifty-seven percent were alive at 1 year (95% Cl, 37%, to 76%). Conclusion: This trial does not support the routine use of thalidomide to induce partial response for metastatic RCC. Because disease stabilization occurs as a part of the natural history of metastatic RCC, the potential effect of thalidomide on progression-free and overall survival for patients with advanced RCC is being addressed in a randomized phase III trial. New immunomodulatory analogs of thalidomide that have shown potentially greater antitumor effects in preclinical models warrant study in metastatic RCC.

UR - http://www.scopus.com/inward/record.url?scp=0036139999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036139999&partnerID=8YFLogxK

U2 - 10.1200/JCO.20.1.302

DO - 10.1200/JCO.20.1.302

M3 - Article

C2 - 11773183

AN - SCOPUS:0036139999

VL - 20

SP - 302

EP - 306

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -